218 related articles for article (PubMed ID: 2161846)
21. Plasminogen activation in bullous pemphigoid immunohistology reveals urokinase type plasminogen activator, its receptor and plasminogen activator inhibitor type-2 in lesional epidermis.
Schaefer BM; Jaeger C; Drepper E; Kramer MD
Autoimmunity; 1996; 23(3):155-64. PubMed ID: 8879451
[TBL] [Abstract][Full Text] [Related]
22. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor.
Ellis V; Behrendt N; Danø K
J Biol Chem; 1991 Jul; 266(19):12752-8. PubMed ID: 1829461
[TBL] [Abstract][Full Text] [Related]
23. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).
Kobayashi H; Schmitt M; Goretzki L; Chucholowski N; Calvete J; Kramer M; Günzler WA; Jänicke F; Graeff H
J Biol Chem; 1991 Mar; 266(8):5147-52. PubMed ID: 1900515
[TBL] [Abstract][Full Text] [Related]
24. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
25. Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells. Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface.
Ragno P; Montuori N; Rossi G
Eur J Biochem; 1995 Oct; 233(2):514-9. PubMed ID: 7588796
[TBL] [Abstract][Full Text] [Related]
26. [The clinical prospects for the study of the plasminogen activation system in breast cancer].
Gershteĭn ES; Kushlinskiĭ NE
Vestn Ross Akad Med Nauk; 1999; (8):58-61. PubMed ID: 10487126
[TBL] [Abstract][Full Text] [Related]
27. A high-affinity receptor for urokinase plasminogen activator on human keratinocytes: characterization and potential modulation during migration.
McNeill H; Jensen PJ
Cell Regul; 1990 Oct; 1(11):843-52. PubMed ID: 1965151
[TBL] [Abstract][Full Text] [Related]
28. Urokinase expression in mononuclear phagocytes: cytokine-specific modulation by interferon-gamma and tumor necrosis factor-alpha.
Gyetko MR; Shollenberger SB; Sitrin RG
J Leukoc Biol; 1992 Mar; 51(3):256-63. PubMed ID: 1311745
[TBL] [Abstract][Full Text] [Related]
29. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading.
Planus E; Barlovatz-Meimon G; Rogers RA; Bonavaud S; Ingber DE; Wang N
J Cell Sci; 1997 May; 110 ( Pt 9)():1091-8. PubMed ID: 9175705
[TBL] [Abstract][Full Text] [Related]
30. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation.
Conese M; Blasi F
Biol Chem Hoppe Seyler; 1995 Mar; 376(3):143-55. PubMed ID: 7612191
[TBL] [Abstract][Full Text] [Related]
31. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
Reinartz J; Link J; Todd RF; Kramer MD
Exp Cell Res; 1994 Oct; 214(2):486-98. PubMed ID: 7925643
[TBL] [Abstract][Full Text] [Related]
32. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system.
Behrendt N; Danø K
FEBS Lett; 1996 Sep; 393(1):31-6. PubMed ID: 8804418
[TBL] [Abstract][Full Text] [Related]
33. Cell-surface acceleration of urokinase-catalyzed receptor cleavage.
Høyer-Hansen G; Ploug M; Behrendt N; Rønne E; Danø K
Eur J Biochem; 1997 Jan; 243(1-2):21-6. PubMed ID: 9030717
[TBL] [Abstract][Full Text] [Related]
34. Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy.
Lundgren CH; Sawa H; Sobel BE; Fujii S
Circulation; 1994 Oct; 90(4):1927-34. PubMed ID: 7923681
[TBL] [Abstract][Full Text] [Related]
35. Autocrine saturation of pro-urokinase receptors on human A431 cells.
Stoppelli MP; Tacchetti C; Cubellis MV; Corti A; Hearing VJ; Cassani G; Appella E; Blasi F
Cell; 1986 Jun; 45(5):675-84. PubMed ID: 3011276
[TBL] [Abstract][Full Text] [Related]
36. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
[TBL] [Abstract][Full Text] [Related]
37. Plasminogen activator system in pemphigus vulgaris.
Schaefer BM; Jaeger CJ; Kramer MD
Br J Dermatol; 1996 Nov; 135(5):726-32. PubMed ID: 8977672
[TBL] [Abstract][Full Text] [Related]
38. Functional characteristics of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors.
Kirchheimer JC; Remold HG
Blood; 1989 Sep; 74(4):1396-402. PubMed ID: 2548640
[TBL] [Abstract][Full Text] [Related]
39. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer.
Duggan C; Maguire T; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
Int J Cancer; 1995 May; 61(5):597-600. PubMed ID: 7768629
[TBL] [Abstract][Full Text] [Related]
40. The THP-1 cell line is a urokinase-secreting mononuclear phagocyte with a novel defect in the production of plasminogen activator inhibitor-2.
Gross TJ; Sitrin RG
J Immunol; 1990 Mar; 144(5):1873-9. PubMed ID: 2307845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
